At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 739 enrolled
Drug / intervention
VESIcare® +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5mg and 10mg VESIcare® for the Treatment of Urgency Associated With Overactive Bladder
In Brief
A Phase 3 clinical trial evaluating VESIcare® and placebo for Urinary Bladder, Overactive. Completed, enrolled 739 participants across 65 sites.
Detailed Summary
The purpose is to evaluate the efficacy of 5 and 10mg VESIcare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder, Overactive
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2004
Primary CompletionSep 2005
First PostedApr 2007
TodayJul 2026
First PostedApr 2, 2007
Enrollment StartMay 1, 2004
Primary CompletionSep 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.3 years ago
Interventions
VESIcare®drug
Oral
placebodrug
Oral